BindingDB logo
myBDB logout

Patent code US9630949

Compile Data Set for Download or QSAR
Found 143 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323175
PNG
(N-[(S)-1-[(S)-2-(3-hydroxy-3-o-tolylazetidin-1-yl)...)
Show SMILES COc1ccc(C[C@H](NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)c2ccccc2)C(=O)N2CC(O)(C2)c2ccccc2C)cc1
Show InChI InChI=1S/C33H35N5O5/c1-22-8-6-7-11-27(22)33(42)19-38(20-33)32(41)29(16-23-12-14-26(43-2)15-13-23)37-31(40)28(17-25-18-34-21-35-25)36-30(39)24-9-4-3-5-10-24/h3-15,18,21,28-29,42H,16-17,19-20H2,1-2H3,(H,34,35)(H,36,39)(H,37,40)/t28-,29-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323178
PNG
(N-[(S)-1-[(S)-2-(3-cyclohexyl-3-hydroxyazetidin-1-...)
Show SMILES COc1ccc(C[C@H](NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)c2ccccc2)C(=O)N2CC(O)(C2)C2CCCCC2)cc1
Show InChI InChI=1S/C32H39N5O5/c1-42-26-14-12-22(13-15-26)16-28(31(40)37-19-32(41,20-37)24-10-6-3-7-11-24)36-30(39)27(17-25-18-33-21-34-25)35-29(38)23-8-4-2-5-9-23/h2,4-5,8-9,12-15,18,21,24,27-28,41H,3,6-7,10-11,16-17,19-20H2,1H3,(H,33,34)(H,35,38)(H,36,39)/t27-,28-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323179
PNG
(N-[(S)-1-[(S)-2-[3-butoxy-3-(4-fluorophenyl)azetid...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)c1ccccc1)c1ccc(F)cc1
Show InChI InChI=1S/C36H40FN5O5/c1-3-4-18-47-36(27-12-14-28(37)15-13-27)22-42(23-36)35(45)32(19-25-10-16-30(46-2)17-11-25)41-34(44)31(20-29-21-38-24-39-29)40-33(43)26-8-6-5-7-9-26/h5-17,21,24,31-32H,3-4,18-20,22-23H2,1-2H3,(H,38,39)(H,40,43)(H,41,44)/t31-,32-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323186
PNG
(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C30H38N4O4/c1-4-5-16-38-30(26-9-7-6-8-22(26)2)19-34(20-30)29(36)27(17-23-10-13-25(37-3)14-11-23)33-28(35)15-12-24-18-31-21-32-24/h6-11,13-14,18,21,27H,4-5,12,15-17,19-20H2,1-3H3,(H,31,32)(H,33,35)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323187
PNG
(N-[(S)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C30H38N4O4/c1-4-5-16-38-30(26-9-7-6-8-22(26)2)19-34(20-30)29(36)27(17-23-10-13-25(37-3)14-11-23)33-28(35)15-12-24-18-31-21-32-24/h6-11,13-14,18,21,27H,4-5,12,15-17,19-20H2,1-3H3,(H,31,32)(H,33,35)/t27-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.50E+4n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323193
PNG
(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-propoxy-3-o-...)
Show SMILES CCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C29H36N4O4/c1-4-15-37-29(25-8-6-5-7-21(25)2)18-33(19-29)28(35)26(16-22-9-12-24(36-3)13-10-22)32-27(34)14-11-23-17-30-20-31-23/h5-10,12-13,17,20,26H,4,11,14-16,18-19H2,1-3H3,(H,30,31)(H,32,34)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+4n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323195
PNG
(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyloxy-3-...)
Show SMILES CCCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C31H40N4O4/c1-4-5-8-17-39-31(27-10-7-6-9-23(27)2)20-35(21-31)30(37)28(18-24-11-14-26(38-3)15-12-24)34-29(36)16-13-25-19-32-22-33-25/h6-7,9-12,14-15,19,22,28H,4-5,8,13,16-18,20-21H2,1-3H3,(H,32,33)(H,34,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 250n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323195
PNG
(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyloxy-3-...)
Show SMILES CCCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C31H40N4O4/c1-4-5-8-17-39-31(27-10-7-6-9-23(27)2)20-35(21-31)30(37)28(18-24-11-14-26(38-3)15-12-24)34-29(36)16-13-25-19-32-22-33-25/h6-7,9-12,14-15,19,22,28H,4-5,8,13,16-18,20-21H2,1-3H3,(H,32,33)(H,34,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323196
PNG
(N-[(R)-2-(3-hexyloxy-3-o-tolylazetidin-1-yl)-1-(4-...)
Show SMILES CCCCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C32H42N4O4/c1-4-5-6-9-18-40-32(28-11-8-7-10-24(28)2)21-36(22-32)31(38)29(19-25-12-15-27(39-3)16-13-25)35-30(37)17-14-26-20-33-23-34-26/h7-8,10-13,15-16,20,23,29H,4-6,9,14,17-19,21-22H2,1-3H3,(H,33,34)(H,35,37)/t29-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323202
PNG
(N-[(R)-2-[3-butoxy-3-(4-fluorophenyl)azetidin-1-yl...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(F)cc1)NC(=O)CCc1c[nH]cn1)c1ccc(F)cc1
Show InChI InChI=1S/C28H32F2N4O3/c1-2-3-14-37-28(21-6-10-23(30)11-7-21)17-34(18-28)27(36)25(15-20-4-8-22(29)9-5-20)33-26(35)13-12-24-16-31-19-32-24/h4-11,16,19,25H,2-3,12-15,17-18H2,1H3,(H,31,32)(H,33,35)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323203
PNG
(N-[(R)-2-(3-butoxy-3-phenylazetidin-1-yl)-1-(4-flu...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(F)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C28H33FN4O3/c1-2-3-15-36-28(22-7-5-4-6-8-22)18-33(19-28)27(35)25(16-21-9-11-23(29)12-10-21)32-26(34)14-13-24-17-30-20-31-24/h4-12,17,20,25H,2-3,13-16,18-19H2,1H3,(H,30,31)(H,32,34)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323206
PNG
(N-[(R)-2-(3-butoxy-3-phenylazetidin-1-yl)-1-(4-met...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H36N4O4/c1-3-4-16-37-29(23-8-6-5-7-9-23)19-33(20-29)28(35)26(17-22-10-13-25(36-2)14-11-22)32-27(34)15-12-24-18-30-21-31-24/h5-11,13-14,18,21,26H,3-4,12,15-17,19-20H2,1-2H3,(H,30,31)(H,32,34)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323225
PNG
(N-[(R)-2-[3-(3-fluorophenyl)-3-pentylazetidin-1-yl...)
Show SMILES CCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1cccc(F)c1
Show InChI InChI=1S/C28H33FN4O3/c1-3-13-28(21-5-4-6-22(29)15-21)17-33(18-28)27(35)25(14-20-7-10-24(36-2)11-8-20)32-26(34)12-9-23-16-30-19-31-23/h4-8,10-11,15-16,19,25H,3,9,12-14,17-18H2,1-2H3,(H,30,31)(H,32,34)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 120n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323225
PNG
(N-[(R)-2-[3-(3-fluorophenyl)-3-pentylazetidin-1-yl...)
Show SMILES CCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1cccc(F)c1
Show InChI InChI=1S/C28H33FN4O3/c1-3-13-28(21-5-4-6-22(29)15-21)17-33(18-28)27(35)25(14-20-7-10-24(36-2)11-8-20)32-26(34)12-9-23-16-30-19-31-23/h4-8,10-11,15-16,19,25H,3,9,12-14,17-18H2,1-2H3,(H,30,31)(H,32,34)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323226
PNG
(N-[(R)-1-(3-fluorobenzyl)-2-oxo-2-(3-pentyl-3-phen...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1cccc(F)c1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H35FN4O2/c1-2-3-7-15-29(23-10-5-4-6-11-23)19-34(20-29)28(36)26(17-22-9-8-12-24(30)16-22)33-27(35)14-13-25-18-31-21-32-25/h4-6,8-12,16,18,21,26H,2-3,7,13-15,17,19-20H2,1H3,(H,31,32)(H,33,35)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323234
PNG
(N-[2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-methox...)
Show SMILES CCCCOC1(CN(C1)C(=O)C(Cc1ccc(OC)cc1)[N-]CCC(CC)c1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C32H43N4O3/c1-5-7-18-39-32(28-11-9-8-10-24(28)3)21-36(22-32)31(37)29(19-25-12-14-27(38-4)15-13-25)34-17-16-26(6-2)30-20-33-23-35-30/h8-15,20,23,26,29H,5-7,16-19,21-22H2,1-4H3,(H,33,35)/q-1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323238
PNG
(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1cncn1C)c1ccccc1C
Show InChI InChI=1S/C31H40N4O4/c1-5-6-17-39-31(27-10-8-7-9-23(27)2)20-35(21-31)30(37)28(18-24-11-14-26(38-4)15-12-24)33-29(36)16-13-25-19-32-22-34(25)3/h7-12,14-15,19,22,28H,5-6,13,16-18,20-21H2,1-4H3,(H,33,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323239
PNG
(N-[(R)-2-[3-Butoxy-3-(2-fluorophenyl)azetidin-1-yl...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1F
Show InChI InChI=1S/C29H35FN4O4/c1-3-4-15-38-29(24-7-5-6-8-25(24)30)18-34(19-29)28(36)26(16-21-9-12-23(37-2)13-10-21)33-27(35)14-11-22-17-31-20-32-22/h5-10,12-13,17,20,26H,3-4,11,14-16,18-19H2,1-2H3,(H,31,32)(H,33,35)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 60n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323241
PNG
(N-[2-(3-Butoxy-3-o-tolylazetidin-1-yl)-1-(2-hydrox...)
Show SMILES CCCCOC1(CN(C1)C(=O)C(Cc1ccc(OC)cc1O)NC(=O)CCc1cnc[nH]1)c1ccccc1C
Show InChI InChI=1S/C30H38N4O5/c1-4-5-14-39-30(25-9-7-6-8-21(25)2)18-34(19-30)29(37)26(15-22-10-12-24(38-3)16-27(22)35)33-28(36)13-11-23-17-31-20-32-23/h6-10,12,16-17,20,26,35H,4-5,11,13-15,18-19H2,1-3H3,(H,31,32)(H,33,36)
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323253
PNG
((S)-N-[(R)-2-(3-Butoxy-3-o-tolylazetidin-1-yl)-1-(...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](O)Cc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C30H38N4O5/c1-4-5-14-39-30(25-9-7-6-8-21(25)2)18-34(19-30)29(37)26(15-22-10-12-24(38-3)13-11-22)33-28(36)27(35)16-23-17-31-20-32-23/h6-13,17,20,26-27,35H,4-5,14-16,18-19H2,1-3H3,(H,31,32)(H,33,36)/t26-,27+/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 60n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323172
PNG
(N-[(S)-1-[(S)-2-(3-Butoxy-3-phenylazetidin-1-yl)-1...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)c1ccccc1)c1ccccc1
Show InChI InChI=1S/C36H41N5O5/c1-3-4-19-46-36(28-13-9-6-10-14-28)23-41(24-36)35(44)32(20-26-15-17-30(45-2)18-16-26)40-34(43)31(21-29-22-37-25-38-29)39-33(42)27-11-7-5-8-12-27/h5-18,22,25,31-32H,3-4,19-21,23-24H2,1-2H3,(H,37,38)(H,39,42)(H,40,43)/t31-,32-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323172
PNG
(N-[(S)-1-[(S)-2-(3-Butoxy-3-phenylazetidin-1-yl)-1...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)c1ccccc1)c1ccccc1
Show InChI InChI=1S/C36H41N5O5/c1-3-4-19-46-36(28-13-9-6-10-14-28)23-41(24-36)35(44)32(20-26-15-17-30(45-2)18-16-26)40-34(43)31(21-29-22-37-25-38-29)39-33(42)27-11-7-5-8-12-27/h5-18,22,25,31-32H,3-4,19-21,23-24H2,1-2H3,(H,37,38)(H,39,42)(H,40,43)/t31-,32-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323183
PNG
(N-[(R)-1-(3,4-dichlorobenzyl)-2-(3-hydroxy-3-pheny...)
Show SMILES OC1(CN(C1)C(=O)[C@@H](Cc1ccc(Cl)c(Cl)c1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C24H24Cl2N4O3/c25-19-8-6-16(10-20(19)26)11-21(29-22(31)9-7-18-12-27-15-28-18)23(32)30-13-24(33,14-30)17-4-2-1-3-5-17/h1-6,8,10,12,15,21,33H,7,9,11,13-14H2,(H,27,28)(H,29,31)/t21-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323189
PNG
(N-[(R)-2-(3-butoxy-3-phenylazetidin-1-yl)-1-cycloh...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](CC1CCCCC1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C28H40N4O3/c1-2-3-16-35-28(23-12-8-5-9-13-23)19-32(20-28)27(34)25(17-22-10-6-4-7-11-22)31-26(33)15-14-24-18-29-21-30-24/h5,8-9,12-13,18,21-22,25H,2-4,6-7,10-11,14-17,19-20H2,1H3,(H,29,30)(H,31,33)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323190
PNG
(N-[(R)-2-(3-butoxy-3-phenylazetidin-1-yl)-1-(2,4-d...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(Cl)cc1Cl)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C28H32Cl2N4O3/c1-2-3-13-37-28(21-7-5-4-6-8-21)17-34(18-28)27(36)25(14-20-9-10-22(29)15-24(20)30)33-26(35)12-11-23-16-31-19-32-23/h4-10,15-16,19,25H,2-3,11-14,17-18H2,1H3,(H,31,32)(H,33,35)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323191
PNG
(N-[(R)-2-(3-cyclopropylmethoxy-3-o-tolylazetidin-1...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(C2)(OCC2CC2)c2ccccc2C)cc1
Show InChI InChI=1S/C30H36N4O4/c1-21-5-3-4-6-26(21)30(38-17-23-7-8-23)18-34(19-30)29(36)27(15-22-9-12-25(37-2)13-10-22)33-28(35)14-11-24-16-31-20-32-24/h3-6,9-10,12-13,16,20,23,27H,7-8,11,14-15,17-19H2,1-2H3,(H,31,32)(H,33,35)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323200
PNG
(N-[(R)-2-(3-hydroxy-3-o-tolylazetidin-1-yl)-1-(4-m...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(O)(C2)c2ccccc2C)cc1
Show InChI InChI=1S/C26H30N4O4/c1-18-5-3-4-6-22(18)26(33)15-30(16-26)25(32)23(13-19-7-10-21(34-2)11-8-19)29-24(31)12-9-20-14-27-17-28-20/h3-8,10-11,14,17,23,33H,9,12-13,15-16H2,1-2H3,(H,27,28)(H,29,31)/t23-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323201
PNG
(N-[(R)-2-[3-butoxy-3-(4-fluorophenyl)azetidin-1-yl...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1cccc(F)c1)NC(=O)CCc1c[nH]cn1)c1ccc(F)cc1
Show InChI InChI=1S/C28H32F2N4O3/c1-2-3-13-37-28(21-7-9-22(29)10-8-21)17-34(18-28)27(36)25(15-20-5-4-6-23(30)14-20)33-26(35)12-11-24-16-31-19-32-24/h4-10,14,16,19,25H,2-3,11-13,15,17-18H2,1H3,(H,31,32)(H,33,35)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323207
PNG
(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyl-3-o-t...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C31H40N4O3/c1-4-5-8-17-31(27-10-7-6-9-23(27)2)20-35(21-31)30(37)28(18-24-11-14-26(38-3)15-12-24)34-29(36)16-13-25-19-32-22-33-25/h6-7,9-12,14-15,19,22,28H,4-5,8,13,16-18,20-21H2,1-3H3,(H,32,33)(H,34,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 250n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323210
PNG
(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCC1N=NC(C)=N1)c1ccccc1C
Show InChI InChI=1S/C30H39N5O4/c1-5-6-17-39-30(25-10-8-7-9-21(25)2)19-35(20-30)29(37)26(18-23-11-13-24(38-4)14-12-23)32-28(36)16-15-27-31-22(3)33-34-27/h7-14,26-27H,5-6,15-20H2,1-4H3,(H,32,36)/t26-,27?/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323215
PNG
(N-[(R)-1-(4-chlorobenzyl)-2-oxo-2-(3-pentyl-3-phen...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H35ClN4O2/c1-2-3-7-16-29(23-8-5-4-6-9-23)19-34(20-29)28(36)26(17-22-10-12-24(30)13-11-22)33-27(35)15-14-25-18-31-21-32-25/h4-6,8-13,18,21,26H,2-3,7,14-17,19-20H2,1H3,(H,31,32)(H,33,35)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323218
PNG
(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)\C=C\c1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C30H36N4O4/c1-4-5-16-38-30(26-9-7-6-8-22(26)2)19-34(20-30)29(36)27(17-23-10-13-25(37-3)14-11-23)33-28(35)15-12-24-18-31-21-32-24/h6-15,18,21,27H,4-5,16-17,19-20H2,1-3H3,(H,31,32)(H,33,35)/b15-12+/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323219
PNG
(N-[(R)-2-[3-(2,4-difluorophenyl)-3-pentylazetidin-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccc(F)cc1F
Show InChI InChI=1S/C30H36F2N4O3/c1-3-4-5-14-30(25-12-8-22(31)16-26(25)32)18-36(19-30)29(38)27(15-21-6-10-24(39-2)11-7-21)35-28(37)13-9-23-17-33-20-34-23/h6-8,10-12,16-17,20,27H,3-5,9,13-15,18-19H2,1-2H3,(H,33,34)(H,35,37)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 15n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323226
PNG
(N-[(R)-1-(3-fluorobenzyl)-2-oxo-2-(3-pentyl-3-phen...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1cccc(F)c1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H35FN4O2/c1-2-3-7-15-29(23-10-5-4-6-11-23)19-34(20-29)28(36)26(17-22-9-8-12-24(30)16-22)33-27(35)14-13-25-18-31-21-32-25/h4-6,8-12,16,18,21,26H,2-3,7,13-15,17,19-20H2,1H3,(H,31,32)(H,33,35)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323230
PNG
(N-[(R)-2-[3-(2,5-difluorophenyl)-3-pentylazetidin-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1cc(F)ccc1F
Show InChI InChI=1S/C30H36F2N4O3/c1-3-4-5-14-30(25-16-22(31)8-12-26(25)32)18-36(19-30)29(38)27(15-21-6-10-24(39-2)11-7-21)35-28(37)13-9-23-17-33-20-34-23/h6-8,10-12,16-17,20,27H,3-5,9,13-15,18-19H2,1-2H3,(H,33,34)(H,35,37)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 100n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323233
PNG
(N-[2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-methox...)
Show SMILES CCCCOC1(CN(C1)C(=O)C(Cc1ccc(OC)cc1)[N-]CCC(CCC)c1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C33H45N4O3/c1-5-7-19-40-33(29-12-9-8-11-25(29)3)22-37(23-33)32(38)30(20-26-13-15-28(39-4)16-14-26)35-18-17-27(10-6-2)31-21-34-24-36-31/h8-9,11-16,21,24,27,30H,5-7,10,17-20,22-23H2,1-4H3,(H,34,36)/q-1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323233
PNG
(N-[2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-methox...)
Show SMILES CCCCOC1(CN(C1)C(=O)C(Cc1ccc(OC)cc1)[N-]CCC(CCC)c1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C33H45N4O3/c1-5-7-19-40-33(29-12-9-8-11-25(29)3)22-37(23-33)32(38)30(20-26-13-15-28(39-4)16-14-26)35-18-17-27(10-6-2)31-21-34-24-36-31/h8-9,11-16,21,24,27,30H,5-7,10,17-20,22-23H2,1-4H3,(H,34,36)/q-1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323256
PNG
(N-[(R)-2-(3-Butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CC(O)c1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C30H38N4O5/c1-4-5-14-39-30(24-9-7-6-8-21(24)2)18-34(19-30)29(37)25(15-22-10-12-23(38-3)13-11-22)33-28(36)16-27(35)26-17-31-20-32-26/h6-13,17,20,25,27,35H,4-5,14-16,18-19H2,1-3H3,(H,31,32)(H,33,36)/t25-,27?/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 250n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323261
PNG
(N-[(R)-2-(3-Cyclobutylmethoxy-3-o-tolylazetidin-1-...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2nc[nH]c2C)C(=O)N2CC(C2)(OCC2CCC2)c2ccccc2C)cc1
Show InChI InChI=1S/C32H40N4O4/c1-22-7-4-5-10-27(22)32(40-18-25-8-6-9-25)19-36(20-32)31(38)29(17-24-11-13-26(39-3)14-12-24)35-30(37)16-15-28-23(2)33-21-34-28/h4-5,7,10-14,21,25,29H,6,8-9,15-20H2,1-3H3,(H,33,34)(H,35,37)/t29-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 15n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323176
PNG
(1-[(S)-2-[(S)-2-benzoylamino-3-(1H-imidazol-4-yl)p...)
Show SMILES COc1ccc(C[C@H](NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)c2ccccc2)C(=O)N2CC(C2)(OC(C)=O)c2ccccc2C)cc1
Show InChI InChI=1S/C35H37N5O6/c1-23-9-7-8-12-29(23)35(46-24(2)41)20-40(21-35)34(44)31(17-25-13-15-28(45-3)16-14-25)39-33(43)30(18-27-19-36-22-37-27)38-32(42)26-10-5-4-6-11-26/h4-16,19,22,30-31H,17-18,20-21H2,1-3H3,(H,36,37)(H,38,42)(H,39,43)/t30-,31-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323178
PNG
(N-[(S)-1-[(S)-2-(3-cyclohexyl-3-hydroxyazetidin-1-...)
Show SMILES COc1ccc(C[C@H](NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)c2ccccc2)C(=O)N2CC(O)(C2)C2CCCCC2)cc1
Show InChI InChI=1S/C32H39N5O5/c1-42-26-14-12-22(13-15-26)16-28(31(40)37-19-32(41,20-37)24-10-6-3-7-11-24)36-30(39)27(17-25-18-33-21-34-25)35-29(38)23-8-4-2-5-9-23/h2,4-5,8-9,12-15,18,21,24,27-28,41H,3,6-7,10-11,16-17,19-20H2,1H3,(H,33,34)(H,35,38)(H,36,39)/t27-,28-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323185
PNG
(N-[(S)-2-(3-cyclopropylmethoxy-3-o-tolylazetidin-1...)
Show SMILES COc1ccc(C[C@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(C2)(OCC2CC2)c2ccccc2C)cc1
Show InChI InChI=1S/C30H36N4O4/c1-21-5-3-4-6-26(21)30(38-17-23-7-8-23)18-34(19-30)29(36)27(15-22-9-12-25(37-2)13-10-22)33-28(35)14-11-24-16-31-20-32-24/h3-6,9-10,12-13,16,20,23,27H,7-8,11,14-15,17-19H2,1-2H3,(H,31,32)(H,33,35)/t27-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323186
PNG
(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C30H38N4O4/c1-4-5-16-38-30(26-9-7-6-8-22(26)2)19-34(20-30)29(36)27(17-23-10-13-25(37-3)14-11-23)33-28(35)15-12-24-18-31-21-32-24/h6-11,13-14,18,21,27H,4-5,12,15-17,19-20H2,1-3H3,(H,31,32)(H,33,35)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 120n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323194
PNG
(N-[(R)-2-[3-butoxy-3-(4-fluorophenyl)azetidin-1-yl...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccc(F)cc1
Show InChI InChI=1S/C29H35FN4O4/c1-3-4-15-38-29(22-7-9-23(30)10-8-22)18-34(19-29)28(36)26(16-21-5-12-25(37-2)13-6-21)33-27(35)14-11-24-17-31-20-32-24/h5-10,12-13,17,20,26H,3-4,11,14-16,18-19H2,1-2H3,(H,31,32)(H,33,35)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323201
PNG
(N-[(R)-2-[3-butoxy-3-(4-fluorophenyl)azetidin-1-yl...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1cccc(F)c1)NC(=O)CCc1c[nH]cn1)c1ccc(F)cc1
Show InChI InChI=1S/C28H32F2N4O3/c1-2-3-13-37-28(21-7-9-22(29)10-8-21)17-34(18-28)27(36)25(15-20-5-4-6-23(30)14-20)33-26(35)12-11-24-16-31-19-32-24/h4-10,14,16,19,25H,2-3,11-13,15,17-18H2,1H3,(H,31,32)(H,33,35)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323203
PNG
(N-[(R)-2-(3-butoxy-3-phenylazetidin-1-yl)-1-(4-flu...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(F)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C28H33FN4O3/c1-2-3-15-36-28(22-7-5-4-6-8-22)18-33(19-28)27(35)25(16-21-9-11-23(29)12-10-21)32-26(34)14-13-24-17-30-20-31-24/h4-12,17,20,25H,2-3,13-16,18-19H2,1H3,(H,30,31)(H,32,34)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323210
PNG
(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCC1N=NC(C)=N1)c1ccccc1C
Show InChI InChI=1S/C30H39N5O4/c1-5-6-17-39-30(25-10-8-7-9-21(25)2)19-35(20-30)29(37)26(18-23-11-13-24(38-4)14-12-23)32-28(36)16-15-27-31-22(3)33-34-27/h7-14,26-27H,5-6,15-20H2,1-4H3,(H,32,36)/t26-,27?/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323211
PNG
(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1[nH]cnc1C)c1ccccc1C
Show InChI InChI=1S/C31H40N4O4/c1-5-6-17-39-31(26-10-8-7-9-22(26)2)19-35(20-31)30(37)28(18-24-11-13-25(38-4)14-12-24)34-29(36)16-15-27-23(3)32-21-33-27/h7-14,21,28H,5-6,15-20H2,1-4H3,(H,32,33)(H,34,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 120n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323216
PNG
(N-[(R)-1-(4-fluorobenzyl)-2-oxo-2-(3-pentyl-3-phen...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(F)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H35FN4O2/c1-2-3-7-16-29(23-8-5-4-6-9-23)19-34(20-29)28(36)26(17-22-10-12-24(30)13-11-22)33-27(35)15-14-25-18-31-21-32-25/h4-6,8-13,18,21,26H,2-3,7,14-17,19-20H2,1H3,(H,31,32)(H,33,35)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323216
PNG
(N-[(R)-1-(4-fluorobenzyl)-2-oxo-2-(3-pentyl-3-phen...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(F)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H35FN4O2/c1-2-3-7-16-29(23-8-5-4-6-9-23)19-34(20-29)28(36)26(17-22-10-12-24(30)13-11-22)33-27(35)15-14-25-18-31-21-32-25/h4-6,8-13,18,21,26H,2-3,7,14-17,19-20H2,1H3,(H,31,32)(H,33,35)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323217
PNG
(N-[(R)-1-benzyl-2-oxo-2-(3-pentyl-3-phenylazetidin...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccccc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H36N4O2/c1-2-3-10-17-29(24-13-8-5-9-14-24)20-33(21-29)28(35)26(18-23-11-6-4-7-12-23)32-27(34)16-15-25-19-30-22-31-25/h4-9,11-14,19,22,26H,2-3,10,15-18,20-21H2,1H3,(H,30,31)(H,32,34)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323218
PNG
(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)\C=C\c1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C30H36N4O4/c1-4-5-16-38-30(26-9-7-6-8-22(26)2)19-34(20-30)29(36)27(17-23-10-13-25(37-3)14-11-23)33-28(35)15-12-24-18-31-21-32-24/h6-15,18,21,27H,4-5,16-17,19-20H2,1-3H3,(H,31,32)(H,33,35)/b15-12+/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323227
PNG
(N-[(R)-1-(2-fluorobenzyl)-2-oxo-2-(3-pentyl-3-phen...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccccc1F)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H35FN4O2/c1-2-3-9-16-29(23-11-5-4-6-12-23)19-34(20-29)28(36)26(17-22-10-7-8-13-25(22)30)33-27(35)15-14-24-18-31-21-32-24/h4-8,10-13,18,21,26H,2-3,9,14-17,19-20H2,1H3,(H,31,32)(H,33,35)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323237
PNG
(N-[(R)-2-(3-cyclohexyl-3-pentylazetidin-1-yl)-1-(4...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)C1CCCCC1
Show InChI InChI=1S/C30H44N4O3/c1-3-4-8-17-30(24-9-6-5-7-10-24)20-34(21-30)29(36)27(18-23-11-14-26(37-2)15-12-23)33-28(35)16-13-25-19-31-22-32-25/h11-12,14-15,19,22,24,27H,3-10,13,16-18,20-21H2,1-2H3,(H,31,32)(H,33,35)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 250n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323259
PNG
(N-[(R)-2-(3-Cyclohexylmethoxy-3-o-tolylazetidin-1-...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(C2)(OCC2CCCCC2)c2ccccc2C)cc1
Show InChI InChI=1S/C33H42N4O4/c1-24-8-6-7-11-29(24)33(41-20-26-9-4-3-5-10-26)21-37(22-33)32(39)30(18-25-12-15-28(40-2)16-13-25)36-31(38)17-14-27-19-34-23-35-27/h6-8,11-13,15-16,19,23,26,30H,3-5,9-10,14,17-18,20-22H2,1-2H3,(H,34,35)(H,36,38)/t30-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 120n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323172
PNG
(N-[(S)-1-[(S)-2-(3-Butoxy-3-phenylazetidin-1-yl)-1...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)c1ccccc1)c1ccccc1
Show InChI InChI=1S/C36H41N5O5/c1-3-4-19-46-36(28-13-9-6-10-14-28)23-41(24-36)35(44)32(20-26-15-17-30(45-2)18-16-26)40-34(43)31(21-29-22-37-25-38-29)39-33(42)27-11-7-5-8-12-27/h5-18,22,25,31-32H,3-4,19-21,23-24H2,1-2H3,(H,37,38)(H,39,42)(H,40,43)/t31-,32-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 60n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323181
PNG
(N-[(S)-2-(3-cyclohexyl-3-hydroxyazetidin-1-yl)-1-(...)
Show SMILES COc1ccc(C[C@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(O)(C2)C2CCCCC2)cc1
Show InChI InChI=1S/C25H34N4O4/c1-33-21-10-7-18(8-11-21)13-22(28-23(30)12-9-20-14-26-17-27-20)24(31)29-15-25(32,16-29)19-5-3-2-4-6-19/h7-8,10-11,14,17,19,22,32H,2-6,9,12-13,15-16H2,1H3,(H,26,27)(H,28,30)/t22-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323182
PNG
(N-[(S)-2-(3-hydroxy-3-o-tolylazetidin-1-yl)-1-(4-m...)
Show SMILES COc1ccc(C[C@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(O)(C2)c2ccccc2C)cc1
Show InChI InChI=1S/C26H30N4O4/c1-18-5-3-4-6-22(18)26(33)15-30(16-26)25(32)23(13-19-7-10-21(34-2)11-8-19)29-24(31)12-9-20-14-27-17-28-20/h3-8,10-11,14,17,23,33H,9,12-13,15-16H2,1-2H3,(H,27,28)(H,29,31)/t23-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323199
PNG
(N-[(R)-2-(3-cyclopropylmethoxy-3-phenylazetidin-1-...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(C2)(OCC2CC2)c2ccccc2)cc1
Show InChI InChI=1S/C29H34N4O4/c1-36-25-12-9-21(10-13-25)15-26(32-27(34)14-11-24-16-30-20-31-24)28(35)33-18-29(19-33,37-17-22-7-8-22)23-5-3-2-4-6-23/h2-6,9-10,12-13,16,20,22,26H,7-8,11,14-15,17-19H2,1H3,(H,30,31)(H,32,34)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323199
PNG
(N-[(R)-2-(3-cyclopropylmethoxy-3-phenylazetidin-1-...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(C2)(OCC2CC2)c2ccccc2)cc1
Show InChI InChI=1S/C29H34N4O4/c1-36-25-12-9-21(10-13-25)15-26(32-27(34)14-11-24-16-30-20-31-24)28(35)33-18-29(19-33,37-17-22-7-8-22)23-5-3-2-4-6-23/h2-6,9-10,12-13,16,20,22,26H,7-8,11,14-15,17-19H2,1H3,(H,30,31)(H,32,34)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323202
PNG
(N-[(R)-2-[3-butoxy-3-(4-fluorophenyl)azetidin-1-yl...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(F)cc1)NC(=O)CCc1c[nH]cn1)c1ccc(F)cc1
Show InChI InChI=1S/C28H32F2N4O3/c1-2-3-14-37-28(21-6-10-23(30)11-7-21)17-34(18-28)27(36)25(15-20-4-8-22(29)9-5-20)33-26(35)13-12-24-16-31-19-32-24/h4-11,16,19,25H,2-3,12-15,17-18H2,1H3,(H,31,32)(H,33,35)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323206
PNG
(N-[(R)-2-(3-butoxy-3-phenylazetidin-1-yl)-1-(4-met...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H36N4O4/c1-3-4-16-37-29(23-8-6-5-7-9-23)19-33(20-29)28(35)26(17-22-10-13-25(36-2)14-11-22)32-27(34)15-12-24-18-30-21-31-24/h5-11,13-14,18,21,26H,3-4,12,15-17,19-20H2,1-2H3,(H,30,31)(H,32,34)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 3.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323207
PNG
(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyl-3-o-t...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C31H40N4O3/c1-4-5-8-17-31(27-10-7-6-9-23(27)2)20-35(21-31)30(37)28(18-24-11-14-26(38-3)15-12-24)34-29(36)16-13-25-19-32-22-33-25/h6-7,9-12,14-15,19,22,28H,4-5,8,13,16-18,20-21H2,1-3H3,(H,32,33)(H,34,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323212
PNG
(N-{(R)-1-(4-methoxybenzyl)-2-[3-(2-methoxyphenyl)-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1OC
Show InChI InChI=1S/C31H40N4O4/c1-4-5-8-17-31(26-9-6-7-10-28(26)39-3)20-35(21-31)30(37)27(18-23-11-14-25(38-2)15-12-23)34-29(36)16-13-24-19-32-22-33-24/h6-7,9-12,14-15,19,22,27H,4-5,8,13,16-18,20-21H2,1-3H3,(H,32,33)(H,34,36)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 60n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323213
PNG
(N-[(R)-2-[3-(2-fluorophenyl)-3-pentylazetidin-1-yl...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1F
Show InChI InChI=1S/C30H37FN4O3/c1-3-4-7-16-30(25-8-5-6-9-26(25)31)19-35(20-30)29(37)27(17-22-10-13-24(38-2)14-11-22)34-28(36)15-12-23-18-32-21-33-23/h5-6,8-11,13-14,18,21,27H,3-4,7,12,15-17,19-20H2,1-2H3,(H,32,33)(H,34,36)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 30n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323214
PNG
(N-[(R)-2-[3-(2-chlorophenyl)-3-pentylazetidin-1-yl...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1Cl
Show InChI InChI=1S/C30H37ClN4O3/c1-3-4-7-16-30(25-8-5-6-9-26(25)31)19-35(20-30)29(37)27(17-22-10-13-24(38-2)14-11-22)34-28(36)15-12-23-18-32-21-33-23/h5-6,8-11,13-14,18,21,27H,3-4,7,12,15-17,19-20H2,1-2H3,(H,32,33)(H,34,36)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 30n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323217
PNG
(N-[(R)-1-benzyl-2-oxo-2-(3-pentyl-3-phenylazetidin...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccccc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H36N4O2/c1-2-3-10-17-29(24-13-8-5-9-14-24)20-33(21-29)28(35)26(18-23-11-6-4-7-12-23)32-27(34)16-15-25-19-30-22-31-25/h4-9,11-14,19,22,26H,2-3,10,15-18,20-21H2,1H3,(H,30,31)(H,32,34)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323223
PNG
(N-[(R)-1-(3,4-difluorobenzyl)-2-oxo-2-(3-pentyl-3-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(F)c(F)c1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H34F2N4O2/c1-2-3-7-14-29(22-8-5-4-6-9-22)18-35(19-29)28(37)26(16-21-10-12-24(30)25(31)15-21)34-27(36)13-11-23-17-32-20-33-23/h4-6,8-10,12,15,17,20,26H,2-3,7,11,13-14,16,18-19H2,1H3,(H,32,33)(H,34,36)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323224
PNG
(N-[(R)-2-[3-(3,4-dichlorophenyl)-3-pentylazetidin-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccc(Cl)c(Cl)c1
Show InChI InChI=1S/C30H36Cl2N4O3/c1-3-4-5-14-30(22-8-12-25(31)26(32)16-22)18-36(19-30)29(38)27(15-21-6-10-24(39-2)11-7-21)35-28(37)13-9-23-17-33-20-34-23/h6-8,10-12,16-17,20,27H,3-5,9,13-15,18-19H2,1-2H3,(H,33,34)(H,35,37)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 250n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323228
PNG
(N-[(R)-1-(2,4-dichlorobenzyl)-2-oxo-2-(3-pentyl-3-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(Cl)cc1Cl)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H34Cl2N4O2/c1-2-3-7-14-29(22-8-5-4-6-9-22)18-35(19-29)28(37)26(15-21-10-11-23(30)16-25(21)31)34-27(36)13-12-24-17-32-20-33-24/h4-6,8-11,16-17,20,26H,2-3,7,12-15,18-19H2,1H3,(H,32,33)(H,34,36)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323235
PNG
(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyl-3-phe...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1cncn1C)c1ccccc1
Show InChI InChI=1S/C31H40N4O3/c1-4-5-9-18-31(25-10-7-6-8-11-25)21-35(22-31)30(37)28(19-24-12-15-27(38-3)16-13-24)33-29(36)17-14-26-20-32-23-34(26)2/h6-8,10-13,15-16,20,23,28H,4-5,9,14,17-19,21-22H2,1-3H3,(H,33,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323239
PNG
(N-[(R)-2-[3-Butoxy-3-(2-fluorophenyl)azetidin-1-yl...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1F
Show InChI InChI=1S/C29H35FN4O4/c1-3-4-15-38-29(24-7-5-6-8-25(24)30)18-34(19-29)28(36)26(16-21-9-12-23(37-2)13-10-21)33-27(35)14-11-22-17-31-20-32-22/h5-10,12-13,17,20,26H,3-4,11,14-16,18-19H2,1-2H3,(H,31,32)(H,33,35)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323240
PNG
(N-[(R)-2-(3-Butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1cn(C)cn1)c1ccccc1C
Show InChI InChI=1S/C31H40N4O4/c1-5-6-17-39-31(27-10-8-7-9-23(27)2)20-35(21-31)30(37)28(18-24-11-14-26(38-4)15-12-24)33-29(36)16-13-25-19-34(3)22-32-25/h7-12,14-15,19,22,28H,5-6,13,16-18,20-21H2,1-4H3,(H,33,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323253
PNG
((S)-N-[(R)-2-(3-Butoxy-3-o-tolylazetidin-1-yl)-1-(...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](O)Cc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C30H38N4O5/c1-4-5-14-39-30(25-9-7-6-8-21(25)2)18-34(19-30)29(37)26(15-22-10-12-24(38-3)13-11-22)33-28(36)27(35)16-23-17-31-20-32-23/h6-13,17,20,26-27,35H,4-5,14-16,18-19H2,1-3H3,(H,31,32)(H,33,36)/t26-,27+/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323256
PNG
(N-[(R)-2-(3-Butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CC(O)c1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C30H38N4O5/c1-4-5-14-39-30(24-9-7-6-8-21(24)2)18-34(19-30)29(37)25(15-22-10-12-23(38-3)13-11-22)33-28(36)16-27(35)26-17-31-20-32-26/h6-13,17,20,25,27,35H,4-5,14-16,18-19H2,1-3H3,(H,31,32)(H,33,36)/t25-,27?/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323257
PNG
(N-[(R)-2-(3-But-2-ynyl-3-o-tolylazetidin-1-yl)-1-(...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(CC#CC)(C2)c2ccccc2C)cc1
Show InChI InChI=1S/C30H34N4O3/c1-4-5-16-30(26-9-7-6-8-22(26)2)19-34(20-30)29(36)27(17-23-10-13-25(37-3)14-11-23)33-28(35)15-12-24-18-31-21-32-24/h6-11,13-14,18,21,27H,12,15-17,19-20H2,1-3H3,(H,31,32)(H,33,35)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 60n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323260
PNG
(3-(1H-Imidazol-4-yl)-N-[(R)-1-(4-methoxybenzyl)-2-...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(C2)(OCCCC(F)(F)F)c2ccccc2C)cc1
Show InChI InChI=1S/C30H35F3N4O4/c1-21-6-3-4-7-25(21)29(41-15-5-14-30(31,32)33)18-37(19-29)28(39)26(16-22-8-11-24(40-2)12-9-22)36-27(38)13-10-23-17-34-20-35-23/h3-4,6-9,11-12,17,20,26H,5,10,13-16,18-19H2,1-2H3,(H,34,35)(H,36,38)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323261
PNG
(N-[(R)-2-(3-Cyclobutylmethoxy-3-o-tolylazetidin-1-...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2nc[nH]c2C)C(=O)N2CC(C2)(OCC2CCC2)c2ccccc2C)cc1
Show InChI InChI=1S/C32H40N4O4/c1-22-7-4-5-10-27(22)32(40-18-25-8-6-9-25)19-36(20-32)31(38)29(17-24-11-13-26(39-3)14-12-24)35-30(37)16-15-28-23(2)33-21-34-28/h4-5,7,10-14,21,25,29H,6,8-9,15-20H2,1-3H3,(H,33,34)(H,35,37)/t29-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323179
PNG
(N-[(S)-1-[(S)-2-[3-butoxy-3-(4-fluorophenyl)azetid...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)c1ccccc1)c1ccc(F)cc1
Show InChI InChI=1S/C36H40FN5O5/c1-3-4-18-47-36(27-12-14-28(37)15-13-27)22-42(23-36)35(45)32(19-25-10-16-30(46-2)17-11-25)41-34(44)31(20-29-21-38-24-39-29)40-33(43)26-8-6-5-7-9-26/h5-17,21,24,31-32H,3-4,18-20,22-23H2,1-2H3,(H,38,39)(H,40,43)(H,41,44)/t31-,32-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 120n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323180
PNG
(N-[(S)-1-[(S)-2-[3-butoxy-3-(3-fluorophenyl)azetid...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)c1ccccc1)c1cccc(F)c1
Show InChI InChI=1S/C36H40FN5O5/c1-3-4-17-47-36(27-11-8-12-28(37)19-27)22-42(23-36)35(45)32(18-25-13-15-30(46-2)16-14-25)41-34(44)31(20-29-21-38-24-39-29)40-33(43)26-9-6-5-7-10-26/h5-16,19,21,24,31-32H,3-4,17-18,20,22-23H2,1-2H3,(H,38,39)(H,40,43)(H,41,44)/t31-,32-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 120n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323197
PNG
(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyl-3-phe...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C30H38N4O3/c1-3-4-8-17-30(24-9-6-5-7-10-24)20-34(21-30)29(36)27(18-23-11-14-26(37-2)15-12-23)33-28(35)16-13-25-19-31-22-32-25/h5-7,9-12,14-15,19,22,27H,3-4,8,13,16-18,20-21H2,1-2H3,(H,31,32)(H,33,35)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323204
PNG
(N-{(R)-1-benzyl-2-[3-butoxy-3-(4-fluoro-phenyl)aze...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccccc1)NC(=O)CCC1=NCC=N1)c1ccc(F)cc1
Show InChI InChI=1S/C28H33FN4O3/c1-2-3-17-36-28(22-9-11-23(29)12-10-22)19-33(20-28)27(35)24(18-21-7-5-4-6-8-21)32-26(34)14-13-25-30-15-16-31-25/h4-12,15,24H,2-3,13-14,16-20H2,1H3,(H,32,34)/t24-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323205
PNG
(N-[(R)-1-benzyl-2-(3-butoxy-3-phenylazetidin-1-yl)...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccccc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C28H34N4O3/c1-2-3-16-35-28(23-12-8-5-9-13-23)19-32(20-28)27(34)25(17-22-10-6-4-7-11-22)31-26(33)15-14-24-18-29-21-30-24/h4-13,18,21,25H,2-3,14-17,19-20H2,1H3,(H,29,30)(H,31,33)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323220
PNG
(N-[(R)-2-oxo-2-(3-pentyl-3-phenylazetidin-1-yl)-1-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1cccc(c1)C(F)(F)F)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C30H35F3N4O2/c1-2-3-7-15-29(23-10-5-4-6-11-23)19-37(20-29)28(39)26(36-27(38)14-13-25-18-34-21-35-25)17-22-9-8-12-24(16-22)30(31,32)33/h4-6,8-12,16,18,21,26H,2-3,7,13-15,17,19-20H2,1H3,(H,34,35)(H,36,38)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323220
PNG
(N-[(R)-2-oxo-2-(3-pentyl-3-phenylazetidin-1-yl)-1-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1cccc(c1)C(F)(F)F)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C30H35F3N4O2/c1-2-3-7-15-29(23-10-5-4-6-11-23)19-37(20-29)28(39)26(36-27(38)14-13-25-18-34-21-35-25)17-22-9-8-12-24(16-22)30(31,32)33/h4-6,8-12,16,18,21,26H,2-3,7,13-15,17,19-20H2,1H3,(H,34,35)(H,36,38)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323221
PNG
(N-[(R)-2-oxo-2-(3-pentyl-3-phenylazetidin-1-yl)-1-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(cc1)C(F)(F)F)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C30H35F3N4O2/c1-2-3-7-16-29(23-8-5-4-6-9-23)19-37(20-29)28(39)26(36-27(38)15-14-25-18-34-21-35-25)17-22-10-12-24(13-11-22)30(31,32)33/h4-6,8-13,18,21,26H,2-3,7,14-17,19-20H2,1H3,(H,34,35)(H,36,38)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323232
PNG
(N-[(R)-2-[3-(2,6-difluorophenyl)-3-pentylazetidin-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1c(F)cccc1F
Show InChI InChI=1S/C30H36F2N4O3/c1-3-4-5-15-30(28-24(31)7-6-8-25(28)32)18-36(19-30)29(38)26(16-21-9-12-23(39-2)13-10-21)35-27(37)14-11-22-17-33-20-34-22/h6-10,12-13,17,20,26H,3-5,11,14-16,18-19H2,1-2H3,(H,33,34)(H,35,37)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 120n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323235
PNG
(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyl-3-phe...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1cncn1C)c1ccccc1
Show InChI InChI=1S/C31H40N4O3/c1-4-5-9-18-31(25-10-7-6-8-11-25)21-35(22-31)30(37)28(19-24-12-15-27(38-3)16-13-24)33-29(36)17-14-26-20-32-23-34(26)2/h6-8,10-13,15-16,20,23,28H,4-5,9,14,17-19,21-22H2,1-3H3,(H,33,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323237
PNG
(N-[(R)-2-(3-cyclohexyl-3-pentylazetidin-1-yl)-1-(4...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)C1CCCCC1
Show InChI InChI=1S/C30H44N4O3/c1-3-4-8-17-30(24-9-6-5-7-10-24)20-34(21-30)29(36)27(18-23-11-14-26(37-2)15-12-23)33-28(35)16-13-25-19-31-22-32-25/h11-12,14-15,19,22,24,27H,3-10,13,16-18,20-21H2,1-2H3,(H,31,32)(H,33,35)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 250n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323255
PNG
(N-[1-(3-Butoxy-3-o-tolylazetidine-1-carbonyl)-2-hy...)
Show SMILES CCCCOC1(CN(C1)C(=O)C(NC(=O)CCc1c[nH]cn1)C(O)c1ccc(OC)cc1)c1ccccc1C
Show InChI InChI=1S/C30H38N4O5/c1-4-5-16-39-30(25-9-7-6-8-21(25)2)18-34(19-30)29(37)27(28(36)22-10-13-24(38-3)14-11-22)33-26(35)15-12-23-17-31-20-32-23/h6-11,13-14,17,20,27-28,36H,4-5,12,15-16,18-19H2,1-3H3,(H,31,32)(H,33,35)
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323258
PNG
(N-[(R)-2-(3-But-2-ynyloxy-3-o-tolylazetidin-1-yl)-...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2nc[nH]c2C)C(=O)N2CC(C2)(OCC#CC)c2ccccc2C)cc1
Show InChI InChI=1S/C31H36N4O4/c1-5-6-17-39-31(26-10-8-7-9-22(26)2)19-35(20-31)30(37)28(18-24-11-13-25(38-4)14-12-24)34-29(36)16-15-27-23(3)32-21-33-27/h7-14,21,28H,15-20H2,1-4H3,(H,32,33)(H,34,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 30n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323173
PNG
(N-[(S)-1-[(S)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)c1ccccc1)c1ccccc1C
Show InChI InChI=1S/C37H43N5O5/c1-4-5-19-47-37(31-14-10-9-11-26(31)2)23-42(24-37)36(45)33(20-27-15-17-30(46-3)18-16-27)41-35(44)32(21-29-22-38-25-39-29)40-34(43)28-12-7-6-8-13-28/h6-18,22,25,32-33H,4-5,19-21,23-24H2,1-3H3,(H,38,39)(H,40,43)(H,41,44)/t32-,33-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323188
PNG
(N-[(R)-2-(3-ethoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C28H34N4O4/c1-4-36-28(24-8-6-5-7-20(24)2)17-32(18-28)27(34)25(15-21-9-12-23(35-3)13-10-21)31-26(33)14-11-22-16-29-19-30-22/h5-10,12-13,16,19,25H,4,11,14-15,17-18H2,1-3H3,(H,29,30)(H,31,33)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 250n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323188
PNG
(N-[(R)-2-(3-ethoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C28H34N4O4/c1-4-36-28(24-8-6-5-7-20(24)2)17-32(18-28)27(34)25(15-21-9-12-23(35-3)13-10-21)31-26(33)14-11-22-16-29-19-30-22/h5-10,12-13,16,19,25H,4,11,14-15,17-18H2,1-3H3,(H,29,30)(H,31,33)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323189
PNG
(N-[(R)-2-(3-butoxy-3-phenylazetidin-1-yl)-1-cycloh...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](CC1CCCCC1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C28H40N4O3/c1-2-3-16-35-28(23-12-8-5-9-13-23)19-32(20-28)27(34)25(17-22-10-6-4-7-11-22)31-26(33)15-14-24-18-29-21-30-24/h5,8-9,12-13,18,21-22,25H,2-4,6-7,10-11,14-17,19-20H2,1H3,(H,29,30)(H,31,33)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323197
PNG
(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyl-3-phe...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C30H38N4O3/c1-3-4-8-17-30(24-9-6-5-7-10-24)20-34(21-30)29(36)27(18-23-11-14-26(37-2)15-12-23)33-28(35)16-13-25-19-31-22-32-25/h5-7,9-12,14-15,19,22,27H,3-4,8,13,16-18,20-21H2,1-2H3,(H,31,32)(H,33,35)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323204
PNG
(N-{(R)-1-benzyl-2-[3-butoxy-3-(4-fluoro-phenyl)aze...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccccc1)NC(=O)CCC1=NCC=N1)c1ccc(F)cc1
Show InChI InChI=1S/C28H33FN4O3/c1-2-3-17-36-28(22-9-11-23(29)12-10-22)19-33(20-28)27(35)24(18-21-7-5-4-6-8-21)32-26(34)14-13-25-30-15-16-31-25/h4-12,15,24H,2-3,13-14,16-20H2,1H3,(H,32,34)/t24-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323205
PNG
(N-[(R)-1-benzyl-2-(3-butoxy-3-phenylazetidin-1-yl)...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccccc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C28H34N4O3/c1-2-3-16-35-28(23-12-8-5-9-13-23)19-32(20-28)27(34)25(17-22-10-6-4-7-11-22)31-26(33)15-14-24-18-29-21-30-24/h4-13,18,21,25H,2-3,14-17,19-20H2,1H3,(H,29,30)(H,31,33)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323208
PNG
(N-[(R)-2-[3-(4-fluorophenyl)-3-pentylazetidin-1-yl...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccc(F)cc1
Show InChI InChI=1S/C30H37FN4O3/c1-3-4-5-16-30(23-8-10-24(31)11-9-23)19-35(20-30)29(37)27(17-22-6-13-26(38-2)14-7-22)34-28(36)15-12-25-18-32-21-33-25/h6-11,13-14,18,21,27H,3-5,12,15-17,19-20H2,1-2H3,(H,32,33)(H,34,36)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 250n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323209
PNG
(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]nn1)c1ccccc1C
Show InChI InChI=1S/C29H37N5O4/c1-4-5-16-38-29(25-9-7-6-8-21(25)2)19-34(20-29)28(36)26(17-22-10-13-24(37-3)14-11-22)31-27(35)15-12-23-18-30-33-32-23/h6-11,13-14,18,26H,4-5,12,15-17,19-20H2,1-3H3,(H,31,35)(H,30,32,33)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323219
PNG
(N-[(R)-2-[3-(2,4-difluorophenyl)-3-pentylazetidin-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccc(F)cc1F
Show InChI InChI=1S/C30H36F2N4O3/c1-3-4-5-14-30(25-12-8-22(31)16-26(25)32)18-36(19-30)29(38)27(15-21-6-10-24(39-2)11-7-21)35-28(37)13-9-23-17-33-20-34-23/h6-8,10-12,16-17,20,27H,3-5,9,13-15,18-19H2,1-2H3,(H,33,34)(H,35,37)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323228
PNG
(N-[(R)-1-(2,4-dichlorobenzyl)-2-oxo-2-(3-pentyl-3-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(Cl)cc1Cl)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H34Cl2N4O2/c1-2-3-7-14-29(22-8-5-4-6-9-22)18-35(19-29)28(37)26(15-21-10-11-23(30)16-25(21)31)34-27(36)13-12-24-17-32-20-33-24/h4-6,8-11,16-17,20,26H,2-3,7,12-15,18-19H2,1H3,(H,32,33)(H,34,36)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323230
PNG
(N-[(R)-2-[3-(2,5-difluorophenyl)-3-pentylazetidin-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1cc(F)ccc1F
Show InChI InChI=1S/C30H36F2N4O3/c1-3-4-5-14-30(25-16-22(31)8-12-26(25)32)18-36(19-30)29(38)27(15-21-6-10-24(39-2)11-7-21)35-28(37)13-9-23-17-33-20-34-23/h6-8,10-12,16-17,20,27H,3-5,9,13-15,18-19H2,1-2H3,(H,33,34)(H,35,37)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 120n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323240
PNG
(N-[(R)-2-(3-Butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1cn(C)cn1)c1ccccc1C
Show InChI InChI=1S/C31H40N4O4/c1-5-6-17-39-31(27-10-8-7-9-23(27)2)20-35(21-31)30(37)28(18-24-11-14-26(38-4)15-12-24)33-29(36)16-13-25-19-34(3)22-32-25/h7-12,14-15,19,22,28H,5-6,13,16-18,20-21H2,1-4H3,(H,33,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323254
PNG
(N-[(R)-2-(3-Butoxy-3-o-tolylazetidin-1-yl)-1-(4-hy...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(O)cc1)NC(=O)CCc1cnc[nH]1)c1ccccc1C
Show InChI InChI=1S/C29H36N4O4/c1-3-4-15-37-29(25-8-6-5-7-21(25)2)18-33(19-29)28(36)26(16-22-9-12-24(34)13-10-22)32-27(35)14-11-23-17-30-20-31-23/h5-10,12-13,17,20,26,34H,3-4,11,14-16,18-19H2,1-2H3,(H,30,31)(H,32,35)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323262
PNG
(N-[(R)-1-(4-Methoxybenzyl)-2-[3-(3-methylbut-2-eny...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2nc[nH]c2C)C(=O)N2CC(C2)(OCC=C(C)C)c2ccccc2C)cc1
Show InChI InChI=1S/C32H40N4O4/c1-22(2)16-17-40-32(27-9-7-6-8-23(27)3)19-36(20-32)31(38)29(18-25-10-12-26(39-5)13-11-25)35-30(37)15-14-28-24(4)33-21-34-28/h6-13,16,21,29H,14-15,17-20H2,1-5H3,(H,33,34)(H,35,37)/t29-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323173
PNG
(N-[(S)-1-[(S)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)c1ccccc1)c1ccccc1C
Show InChI InChI=1S/C37H43N5O5/c1-4-5-19-47-37(31-14-10-9-11-26(31)2)23-42(24-37)36(45)33(20-27-15-17-30(46-3)18-16-27)41-35(44)32(21-29-22-38-25-39-29)40-34(43)28-12-7-6-8-13-28/h6-18,22,25,32-33H,4-5,19-21,23-24H2,1-3H3,(H,38,39)(H,40,43)(H,41,44)/t32-,33-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 30n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323175
PNG
(N-[(S)-1-[(S)-2-(3-hydroxy-3-o-tolylazetidin-1-yl)...)
Show SMILES COc1ccc(C[C@H](NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)c2ccccc2)C(=O)N2CC(O)(C2)c2ccccc2C)cc1
Show InChI InChI=1S/C33H35N5O5/c1-22-8-6-7-11-27(22)33(42)19-38(20-33)32(41)29(16-23-12-14-26(43-2)15-13-23)37-31(40)28(17-25-18-34-21-35-25)36-30(39)24-9-4-3-5-10-24/h3-15,18,21,28-29,42H,16-17,19-20H2,1-2H3,(H,34,35)(H,36,39)(H,37,40)/t28-,29-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 250n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323177
PNG
(1-[(S)-2-[(S)-2-benzoylamino-3-(1H-imidazol-4-yl)p...)
Show SMILES COc1ccc(C[C@H](NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)c2ccccc2)C(=O)N2C[C](C2)c2ccc(F)cc2)cc1
Show InChI InChI=1S/C32H31FN5O4/c1-42-27-13-7-21(8-14-27)15-29(32(41)38-18-24(19-38)22-9-11-25(33)12-10-22)37-31(40)28(16-26-17-34-20-35-26)36-30(39)23-5-3-2-4-6-23/h2-14,17,20,28-29H,15-16,18-19H2,1H3,(H,34,35)(H,36,39)(H,37,40)/t28-,29-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323182
PNG
(N-[(S)-2-(3-hydroxy-3-o-tolylazetidin-1-yl)-1-(4-m...)
Show SMILES COc1ccc(C[C@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(O)(C2)c2ccccc2C)cc1
Show InChI InChI=1S/C26H30N4O4/c1-18-5-3-4-6-22(18)26(33)15-30(16-26)25(32)23(13-19-7-10-21(34-2)11-8-19)29-24(31)12-9-20-14-27-17-28-20/h3-8,10-11,14,17,23,33H,9,12-13,15-16H2,1-2H3,(H,27,28)(H,29,31)/t23-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323184
PNG
(N-[(S)-2-(3-ethoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C28H34N4O4/c1-4-36-28(24-8-6-5-7-20(24)2)17-32(18-28)27(34)25(15-21-9-12-23(35-3)13-10-21)31-26(33)14-11-22-16-29-19-30-22/h5-10,12-13,16,19,25H,4,11,14-15,17-18H2,1-3H3,(H,29,30)(H,31,33)/t25-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.50E+4n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323190
PNG
(N-[(R)-2-(3-butoxy-3-phenylazetidin-1-yl)-1-(2,4-d...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(Cl)cc1Cl)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C28H32Cl2N4O3/c1-2-3-13-37-28(21-7-5-4-6-8-21)17-34(18-28)27(36)25(14-20-9-10-22(29)15-24(20)30)33-26(35)12-11-23-16-31-19-32-23/h4-10,15-16,19,25H,2-3,11-14,17-18H2,1H3,(H,31,32)(H,33,35)/t25-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 120n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323191
PNG
(N-[(R)-2-(3-cyclopropylmethoxy-3-o-tolylazetidin-1...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(C2)(OCC2CC2)c2ccccc2C)cc1
Show InChI InChI=1S/C30H36N4O4/c1-21-5-3-4-6-26(21)30(38-17-23-7-8-23)18-34(19-30)29(36)27(15-22-9-12-25(37-2)13-10-22)33-28(35)14-11-24-16-31-20-32-24/h3-6,9-10,12-13,16,20,23,27H,7-8,11,14-15,17-19H2,1-2H3,(H,31,32)(H,33,35)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 120n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323192
PNG
(N-[(S)-1-(4-methoxybenzyl)-2-oxo-2-(3-propoxy-3-o-...)
Show SMILES CCCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C29H36N4O4/c1-4-15-37-29(25-8-6-5-7-21(25)2)18-33(19-29)28(35)26(16-22-9-12-24(36-3)13-10-22)32-27(34)14-11-23-17-30-20-31-23/h5-10,12-13,17,20,26H,4,11,14-16,18-19H2,1-3H3,(H,30,31)(H,32,34)/t26-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323193
PNG
(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-propoxy-3-o-...)
Show SMILES CCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C29H36N4O4/c1-4-15-37-29(25-8-6-5-7-21(25)2)18-33(19-29)28(35)26(16-22-9-12-24(36-3)13-10-22)32-27(34)14-11-23-17-30-20-31-23/h5-10,12-13,17,20,26H,4,11,14-16,18-19H2,1-3H3,(H,30,31)(H,32,34)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 120n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323194
PNG
(N-[(R)-2-[3-butoxy-3-(4-fluorophenyl)azetidin-1-yl...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccc(F)cc1
Show InChI InChI=1S/C29H35FN4O4/c1-3-4-15-38-29(22-7-9-23(30)10-8-22)18-34(19-29)28(36)26(16-21-5-12-25(37-2)13-6-21)33-27(35)14-11-24-17-31-20-32-24/h5-10,12-13,17,20,26H,3-4,11,14-16,18-19H2,1-2H3,(H,31,32)(H,33,35)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 60n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323196
PNG
(N-[(R)-2-(3-hexyloxy-3-o-tolylazetidin-1-yl)-1-(4-...)
Show SMILES CCCCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C32H42N4O4/c1-4-5-6-9-18-40-32(28-11-8-7-10-24(28)2)21-36(22-32)31(38)29(19-25-12-15-27(39-3)16-13-25)35-30(37)17-14-26-20-33-23-34-26/h7-8,10-13,15-16,20,23,29H,4-6,9,14,17-19,21-22H2,1-3H3,(H,33,34)(H,35,37)/t29-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323209
PNG
(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]nn1)c1ccccc1C
Show InChI InChI=1S/C29H37N5O4/c1-4-5-16-38-29(25-9-7-6-8-21(25)2)19-34(20-29)28(36)26(17-22-10-13-24(37-3)14-11-22)31-27(35)15-12-23-18-30-33-32-23/h6-11,13-14,18,26H,4-5,12,15-17,19-20H2,1-3H3,(H,31,35)(H,30,32,33)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323211
PNG
(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1[nH]cnc1C)c1ccccc1C
Show InChI InChI=1S/C31H40N4O4/c1-5-6-17-39-31(26-10-8-7-9-22(26)2)19-35(20-31)30(37)28(18-24-11-13-25(38-4)14-12-24)34-29(36)16-15-27-23(3)32-21-33-27/h7-14,21,28H,5-6,15-20H2,1-4H3,(H,32,33)(H,34,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323212
PNG
(N-{(R)-1-(4-methoxybenzyl)-2-[3-(2-methoxyphenyl)-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1OC
Show InChI InChI=1S/C31H40N4O4/c1-4-5-8-17-31(26-9-6-7-10-28(26)39-3)20-35(21-31)30(37)27(18-23-11-14-25(38-2)15-12-23)34-29(36)16-13-24-19-32-22-33-24/h6-7,9-12,14-15,19,22,27H,4-5,8,13,16-18,20-21H2,1-3H3,(H,32,33)(H,34,36)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 30n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323215
PNG
(N-[(R)-1-(4-chlorobenzyl)-2-oxo-2-(3-pentyl-3-phen...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H35ClN4O2/c1-2-3-7-16-29(23-8-5-4-6-9-23)19-34(20-29)28(36)26(17-22-10-12-24(30)13-11-22)33-27(35)15-14-25-18-31-21-32-25/h4-6,8-13,18,21,26H,2-3,7,14-17,19-20H2,1H3,(H,31,32)(H,33,35)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323223
PNG
(N-[(R)-1-(3,4-difluorobenzyl)-2-oxo-2-(3-pentyl-3-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(F)c(F)c1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H34F2N4O2/c1-2-3-7-14-29(22-8-5-4-6-9-22)18-35(19-29)28(37)26(16-21-10-12-24(30)25(31)15-21)34-27(36)13-11-23-17-32-20-33-23/h4-6,8-10,12,15,17,20,26H,2-3,7,11,13-14,16,18-19H2,1H3,(H,32,33)(H,34,36)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323227
PNG
(N-[(R)-1-(2-fluorobenzyl)-2-oxo-2-(3-pentyl-3-phen...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccccc1F)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H35FN4O2/c1-2-3-9-16-29(23-11-5-4-6-12-23)19-34(20-29)28(36)26(17-22-10-7-8-13-25(22)30)33-27(35)15-14-24-18-31-21-32-24/h4-8,10-13,18,21,26H,2-3,9,14-17,19-20H2,1H3,(H,31,32)(H,33,35)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323238
PNG
(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1cncn1C)c1ccccc1C
Show InChI InChI=1S/C31H40N4O4/c1-5-6-17-39-31(27-10-8-7-9-23(27)2)20-35(21-31)30(37)28(18-24-11-14-26(38-4)15-12-24)33-29(36)16-13-25-19-32-22-34(25)3/h7-12,14-15,19,22,28H,5-6,13,16-18,20-21H2,1-4H3,(H,33,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323255
PNG
(N-[1-(3-Butoxy-3-o-tolylazetidine-1-carbonyl)-2-hy...)
Show SMILES CCCCOC1(CN(C1)C(=O)C(NC(=O)CCc1c[nH]cn1)C(O)c1ccc(OC)cc1)c1ccccc1C
Show InChI InChI=1S/C30H38N4O5/c1-4-5-16-39-30(25-9-7-6-8-21(25)2)18-34(19-30)29(37)27(28(36)22-10-13-24(38-3)14-11-22)33-26(35)15-12-23-17-31-20-32-23/h6-11,13-14,17,20,27-28,36H,4-5,12,15-16,18-19H2,1-3H3,(H,31,32)(H,33,35)
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323257
PNG
(N-[(R)-2-(3-But-2-ynyl-3-o-tolylazetidin-1-yl)-1-(...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(CC#CC)(C2)c2ccccc2C)cc1
Show InChI InChI=1S/C30H34N4O3/c1-4-5-16-30(26-9-7-6-8-22(26)2)19-34(20-30)29(36)27(17-23-10-13-25(37-3)14-11-23)33-28(35)15-12-24-18-31-21-32-24/h6-11,13-14,18,21,27H,12,15-17,19-20H2,1-3H3,(H,31,32)(H,33,35)/t27-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323260
PNG
(3-(1H-Imidazol-4-yl)-N-[(R)-1-(4-methoxybenzyl)-2-...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(C2)(OCCCC(F)(F)F)c2ccccc2C)cc1
Show InChI InChI=1S/C30H35F3N4O4/c1-21-6-3-4-7-25(21)29(41-15-5-14-30(31,32)33)18-37(19-29)28(39)26(16-22-8-11-24(40-2)12-9-22)36-27(38)13-10-23-17-34-20-35-23/h3-4,6-9,11-12,17,20,26H,5,10,13-16,18-19H2,1-2H3,(H,34,35)(H,36,38)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 120n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323176
PNG
(1-[(S)-2-[(S)-2-benzoylamino-3-(1H-imidazol-4-yl)p...)
Show SMILES COc1ccc(C[C@H](NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)c2ccccc2)C(=O)N2CC(C2)(OC(C)=O)c2ccccc2C)cc1
Show InChI InChI=1S/C35H37N5O6/c1-23-9-7-8-12-29(23)35(46-24(2)41)20-40(21-35)34(44)31(17-25-13-15-28(45-3)16-14-25)39-33(43)30(18-27-19-36-22-37-27)38-32(42)26-10-5-4-6-11-26/h4-16,19,22,30-31H,17-18,20-21H2,1-3H3,(H,36,37)(H,38,42)(H,39,43)/t30-,31-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323177
PNG
(1-[(S)-2-[(S)-2-benzoylamino-3-(1H-imidazol-4-yl)p...)
Show SMILES COc1ccc(C[C@H](NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)c2ccccc2)C(=O)N2C[C](C2)c2ccc(F)cc2)cc1
Show InChI InChI=1S/C32H31FN5O4/c1-42-27-13-7-21(8-14-27)15-29(32(41)38-18-24(19-38)22-9-11-25(33)12-10-22)37-31(40)28(16-26-17-34-20-35-26)36-30(39)23-5-3-2-4-6-23/h2-14,17,20,28-29H,15-16,18-19H2,1H3,(H,34,35)(H,36,39)(H,37,40)/t28-,29-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323180
PNG
(N-[(S)-1-[(S)-2-[3-butoxy-3-(3-fluorophenyl)azetid...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)c1ccccc1)c1cccc(F)c1
Show InChI InChI=1S/C36H40FN5O5/c1-3-4-17-47-36(27-11-8-12-28(37)19-27)22-42(23-36)35(45)32(18-25-13-15-30(46-2)16-14-25)41-34(44)31(20-29-21-38-24-39-29)40-33(43)26-9-6-5-7-10-26/h5-16,19,21,24,31-32H,3-4,17-18,20,22-23H2,1-2H3,(H,38,39)(H,40,43)(H,41,44)/t31-,32-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323184
PNG
(N-[(S)-2-(3-ethoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C28H34N4O4/c1-4-36-28(24-8-6-5-7-20(24)2)17-32(18-28)27(34)25(15-21-9-12-23(35-3)13-10-21)31-26(33)14-11-22-16-29-19-30-22/h5-10,12-13,16,19,25H,4,11,14-15,17-18H2,1-3H3,(H,29,30)(H,31,33)/t25-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323185
PNG
(N-[(S)-2-(3-cyclopropylmethoxy-3-o-tolylazetidin-1...)
Show SMILES COc1ccc(C[C@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(C2)(OCC2CC2)c2ccccc2C)cc1
Show InChI InChI=1S/C30H36N4O4/c1-21-5-3-4-6-26(21)30(38-17-23-7-8-23)18-34(19-30)29(36)27(15-22-9-12-25(37-2)13-10-22)33-28(35)14-11-24-16-31-20-32-24/h3-6,9-10,12-13,16,20,23,27H,7-8,11,14-15,17-19H2,1-2H3,(H,31,32)(H,33,35)/t27-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.50E+4n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323187
PNG
(N-[(S)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Show SMILES CCCCOC1(CN(C1)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C30H38N4O4/c1-4-5-16-38-30(26-9-7-6-8-22(26)2)19-34(20-30)29(36)27(17-23-10-13-25(37-3)14-11-23)33-28(35)15-12-24-18-31-21-32-24/h6-11,13-14,18,21,27H,4-5,12,15-17,19-20H2,1-3H3,(H,31,32)(H,33,35)/t27-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323198
PNG
(N-[(R)-2-(3-butyl-3-phenylazetidin-1-yl)-1-(4-meth...)
Show SMILES CCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H36N4O3/c1-3-4-16-29(23-8-6-5-7-9-23)19-33(20-29)28(35)26(17-22-10-13-25(36-2)14-11-22)32-27(34)15-12-24-18-30-21-31-24/h5-11,13-14,18,21,26H,3-4,12,15-17,19-20H2,1-2H3,(H,30,31)(H,32,34)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323198
PNG
(N-[(R)-2-(3-butyl-3-phenylazetidin-1-yl)-1-(4-meth...)
Show SMILES CCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H36N4O3/c1-3-4-16-29(23-8-6-5-7-9-23)19-33(20-29)28(35)26(17-22-10-13-25(36-2)14-11-22)32-27(34)15-12-24-18-30-21-31-24/h5-11,13-14,18,21,26H,3-4,12,15-17,19-20H2,1-2H3,(H,30,31)(H,32,34)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323222
PNG
(N-[(R)-1-(3,4-dichlorobenzyl)-2-oxo-2-(3-pentyl-3-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(Cl)c(Cl)c1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H34Cl2N4O2/c1-2-3-7-14-29(22-8-5-4-6-9-22)18-35(19-29)28(37)26(16-21-10-12-24(30)25(31)15-21)34-27(36)13-11-23-17-32-20-33-23/h4-6,8-10,12,15,17,20,26H,2-3,7,11,13-14,16,18-19H2,1H3,(H,32,33)(H,34,36)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323222
PNG
(N-[(R)-1-(3,4-dichlorobenzyl)-2-oxo-2-(3-pentyl-3-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(Cl)c(Cl)c1)NC(=O)CCc1c[nH]cn1)c1ccccc1
Show InChI InChI=1S/C29H34Cl2N4O2/c1-2-3-7-14-29(22-8-5-4-6-9-22)18-35(19-29)28(37)26(16-21-10-12-24(30)25(31)15-21)34-27(36)13-11-23-17-32-20-33-23/h4-6,8-10,12,15,17,20,26H,2-3,7,11,13-14,16,18-19H2,1H3,(H,32,33)(H,34,36)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 250n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323232
PNG
(N-[(R)-2-[3-(2,6-difluorophenyl)-3-pentylazetidin-...)
Show SMILES CCCCCC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCc1c[nH]cn1)c1c(F)cccc1F
Show InChI InChI=1S/C30H36F2N4O3/c1-3-4-5-15-30(28-24(31)7-6-8-25(28)32)18-36(19-30)29(38)26(16-21-9-12-23(39-2)13-10-21)35-27(37)14-11-22-17-33-20-34-22/h6-10,12-13,17,20,26H,3-5,11,14-16,18-19H2,1-2H3,(H,33,34)(H,35,37)/t26-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 100n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323234
PNG
(N-[2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-methox...)
Show SMILES CCCCOC1(CN(C1)C(=O)C(Cc1ccc(OC)cc1)[N-]CCC(CC)c1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C32H43N4O3/c1-5-7-18-39-32(28-11-9-8-10-24(28)3)21-36(22-32)31(37)29(19-25-12-14-27(38-4)15-13-25)34-17-16-26(6-2)30-20-33-23-35-30/h8-15,20,23,26,29H,5-7,16-19,21-22H2,1-4H3,(H,33,35)/q-1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 500n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323236
PNG
(N-[2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(2,4-dich...)
Show SMILES CCCCOC1(CN(C1)C(=O)C(Cc1ccc(Cl)cc1Cl)[N-]CCC(CCC)c1c[nH]cn1)c1ccccc1C
Show InChI InChI=1S/C32H41Cl2N4O2/c1-4-6-16-40-32(27-11-8-7-10-23(27)3)20-38(21-32)31(39)29(17-25-12-13-26(33)18-28(25)34)36-15-14-24(9-5-2)30-19-35-22-37-30/h7-8,10-13,18-19,22,24,29H,4-6,9,14-17,20-21H2,1-3H3,(H,35,37)/q-1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 100n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323258
PNG
(N-[(R)-2-(3-But-2-ynyloxy-3-o-tolylazetidin-1-yl)-...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2nc[nH]c2C)C(=O)N2CC(C2)(OCC#CC)c2ccccc2C)cc1
Show InChI InChI=1S/C31H36N4O4/c1-5-6-17-39-31(26-10-8-7-9-22(26)2)19-35(20-31)30(37)28(18-24-11-13-25(38-4)14-12-24)34-29(36)16-15-27-23(3)32-21-33-27/h7-14,21,28H,15-20H2,1-4H3,(H,32,33)(H,34,36)/t28-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 4


(Homo sapiens (Human))
BDBM323259
PNG
(N-[(R)-2-(3-Cyclohexylmethoxy-3-o-tolylazetidin-1-...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2c[nH]cn2)C(=O)N2CC(C2)(OCC2CCCCC2)c2ccccc2C)cc1
Show InChI InChI=1S/C33H42N4O4/c1-24-8-6-7-11-29(24)33(41-20-26-9-4-3-5-10-26)21-37(22-33)32(39)30(18-25-12-15-28(40-2)16-13-25)36-31(38)17-14-27-19-34-23-35-27/h6-8,11-13,15-16,19,23,26,30H,3-5,9-10,14,17-18,20-22H2,1-2H3,(H,34,35)(H,36,38)/t30-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.00E+3n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
Melanocortin receptor 1


(Homo sapiens (Human))
BDBM323262
PNG
(N-[(R)-1-(4-Methoxybenzyl)-2-[3-(3-methylbut-2-eny...)
Show SMILES COc1ccc(C[C@@H](NC(=O)CCc2nc[nH]c2C)C(=O)N2CC(C2)(OCC=C(C)C)c2ccccc2C)cc1
Show InChI InChI=1S/C32H40N4O4/c1-22(2)16-17-40-32(27-9-7-6-8-23(27)3)19-36(20-32)31(38)29(18-25-10-12-26(39-5)13-11-25)35-30(37)15-14-28-24(4)33-21-34-28/h6-13,16,21,29H,14-15,17-20H2,1-5H3,(H,33,34)(H,35,37)/t29-/m1/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 15n/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...


US Patent US9630949 (2017)

More data for this
Ligand-Target Pair
* indicates data uncertainty>20%